We aim to become the global biotech company
based on proprietary technology.
R&D based company with mass cell culture technology and cell quality management technology
Patented in countries
leading new drug development market
Enter the global biotech market
with Proprietary technology
Intellectual Property
Cell2in is committed to protect our core technology by establishment of intellectual property in the field of cell therapy
| Name of Technology | Country of Application | Application and Registration No. | Applied and Registered Date |
|---|---|---|---|
| Real-time Imaging Sensor for Measuring Cellular Thiol Levels | Korea | 10-1862581 | 2018. 05. 24 |
| United States | 10.215.757B2 | 2019. 02. 26 | |
| Korea | 10-1983803 | 2019. 05. 23 | |
| United States | 10.620.215 | 2020. 04. 14 | |
| Real-time Fluorescence Imaging Sensor for Estimating the Glutathione in Cellular Organelle and Manufacturing Method Thereof | Korea | 10-2133794 | 2020. 07. 08 |
| Canada (application) | 3.072.434 | 2020. 02. 07 | |
| Australia (application) | 2018320601 | 2020. 02. 19 | |
| United States (application) | 16/640717 | 2020. 02. 20 | |
| Europe (application) | 18848372.1 | 2020. 02. 21 | |
| China (application) | 201880054675.0 | 2020. 02. 21 | |
| India (application) | 202017007994 | 2020. 02. 25 | |
| Japan (application) | 2020-511502 | 2020. 02. 19 | |
| Real-time Fluorescence Imaging Sensor for Estimating the Glutathione in Endoplasmic Reticulum and a Method of Using It | Korea | 10-2019-0178260 | 2019. 12. 30 |
Gene Biomarker
| Name of Technology | Country of Application | Application and Registration No. | Applied and Registered Date |
|---|---|---|---|
| FreSHtracer-based Application of the Genetic Profile of Separated Cells | PCT | PCT/KR 2018/008239 | 2018. 07. 20 |
Stem Cell Therapy
| Name of Technology | Country of Application | Application and Registration No. | Applied and Registered Date |
|---|---|---|---|
| Composite for Treatment of Thrombocytopenia | Korea | 10-2021-0063975 | 2021. 05. 18 |
| Gene Market for Evaluating the Characteristics of Stem Cells and the Use of the Same | Korea | 10-2020-0180455 | 2020. 12. 22 |
Cell Quality Control
| Name of Technology | Country of Application | Application and Registration No. | Applied and Registered Date |
|---|---|---|---|
| Method of Therapeutic Cell Quality Improvement Based on Real-time Glutathione Measurement | Korea | 10-2119714 | 2020. 06. 01 |
| Europe (application) | 18883520.1 | 2020. 05. 27 | |
| China (application) | 201880077266.2 | 2020. 05. 28 | |
| Japan (application) | 2020-546264 | 2020. 05. 27 | |
| United States (application) | 16/767985 | 2020. 05. 28 | |
| Method of Therapeutic Cell Quality Measurement Based on Real-time Glutathione Measurement | Korea | 10-2145929 | 2020. 08. 12 |
| United States (application) | 16/768014 | 2020. 05. 28 | |
| Europe (application) | 18884812.1 | 2020. 05. 27 | |
| China (application) | 201880077236.1 | 2020. 05. 28 | |
| Japan (application) | 2020-546265 | 2020. 05. 27 |
Publication
Cell2in has continuously published its research results through famous academic societies and journals.
Development Technology and astrocytes : J. Song et al., Cografting astrocytes improves cell therapeutic outcomes in a Parkinson’s disease model, JCI, 2018, 128(1), 463-482
Transplantation of neural progenitor cells (NPCs) is a potential therapy for treating neurodegenerative disorders, but this
approach has faced many challenges and limited success, primarily because of inhospitable host brain environments that
interfere with enriched neuron engraftment and function. Astrocytes play neurotrophic roles in the developing and adult
brain, making them potential candidates for helping with modification of hostile brain environments. In this study, we
examined whether astrocytic function could be utilized to overcome the current limitations of cell-based therapies in a murine
model of Parkinson’s disease (PD) that is characterized by dopamine (DA) neuron degeneration in the midbrain. We show
here that cografting astrocytes, especially those derived from the midbrain, remarkably enhanced NPC-based cell therapeutic
outcomes along with robust DA neuron engraftment in PD rats for at least 6 months after transplantation. We further show
that engineering of donor astrocytes with Nurr1 and Foxa2, transcription factors that were recently reported to polarize
harmful immunogenic glia into the neuroprotective form, further promoted the neurotrophic actions of grafted astrocytes in
the cell therapeutic approach. Collectively, these findings suggest that cografting astrocytes could be a potential strategy for
successful cell therapeutic outcomes in neurodegenerative disorders.
approach has faced many challenges and limited success, primarily because of inhospitable host brain environments that
interfere with enriched neuron engraftment and function. Astrocytes play neurotrophic roles in the developing and adult
brain, making them potential candidates for helping with modification of hostile brain environments. In this study, we
examined whether astrocytic function could be utilized to overcome the current limitations of cell-based therapies in a murine
model of Parkinson’s disease (PD) that is characterized by dopamine (DA) neuron degeneration in the midbrain. We show
here that cografting astrocytes, especially those derived from the midbrain, remarkably enhanced NPC-based cell therapeutic
outcomes along with robust DA neuron engraftment in PD rats for at least 6 months after transplantation. We further show
that engineering of donor astrocytes with Nurr1 and Foxa2, transcription factors that were recently reported to polarize
harmful immunogenic glia into the neuroprotective form, further promoted the neurotrophic actions of grafted astrocytes in
the cell therapeutic approach. Collectively, these findings suggest that cografting astrocytes could be a potential strategy for
successful cell therapeutic outcomes in neurodegenerative disorders.